;PMID: 9130517 ;source_file_1222.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..53] = [t:0..53] ;1)sentence:[e:58..119] = [t:58..119] ;2)section:[e:123..176] = [t:123..176] ;3)section:[e:180..253] = [t:180..253] ;4)sentence:[e:257..447] = [t:257..447] ;5)sentence:[e:448..692] = [t:448..692] ;6)sentence:[e:693..742] = [t:693..742] ;7)section:[e:746..790] = [t:746..790] ;section 0 Span:0..53 ;Int Arch Allergy Immunol 1997 May-Jul;113(1-3):184-6 (SEC (FRAG (NNP:[0..3] Int) (NNP:[4..8] Arch) (NNP:[9..16] Allergy) (NNP:[17..24] Immunol) (CD:[26..30] 1997) (MD:[31..34] May) (RB:[34..35] -) (CD:[35..43] Jul;113-LRB-) (CD:[43..44] 1) (HYPH:[44..45] -) (CD:[45..46] 3) (-RRB-:[46..47] -RRB-) (CD:[47..51] :184) (HYPH:[51..52] -) (CD:[52..53] 6))) ;sentence 1 Span:58..119 ;c-kit mutation in a population of patients with mastocytosis. ;[58..63]:gene-rna:"c-kit" ;[106..118]:malignancy:"mastocytosis" (SENT (NP-HLN (NP (NN:[58..63] c-kit) (NN:[64..72] mutation)) (PP (IN:[73..75] in) (NP (NP (DT:[76..77] a) (NN:[78..88] population)) (PP (IN:[89..91] of) (NP (NP (NNS:[92..100] patients)) (PP (IN:[101..105] with) (NP (NN:[106..118] mastocytosis))))))) (.:[118..119] .))) ;section 2 Span:123..176 ;Nagata H, Okada T, Worobec AS, Semere T, Metcalfe DD. (SEC (FRAG (NNP:[123..129] Nagata) (NNP:[130..131] H) (VBD:[131..132] ,) (NNP:[133..138] Okada) (NNP:[139..140] T) (,:[140..141] ,) (NNP:[142..149] Worobec) (NNP:[150..152] AS) (VBD:[152..153] ,) (NNP:[154..160] Semere) (NNP:[161..162] T) (,:[162..163] ,) (NNP:[164..172] Metcalfe) (NNP:[173..176] DD.))) ;section 3 Span:180..253 ;Department of Otolaryngology, Chiba University School of Medicine, Japan. (SEC (FRAG (NNP:[180..190] Department) (IN:[191..193] of) (NNP:[194..208] Otolaryngology) (,:[208..209] ,) (NNP:[210..215] Chiba) (NNP:[216..226] University) (NNP:[227..233] School) (IN:[234..236] of) (NNP:[237..245] Medicine) (,:[245..246] ,) (NNP:[247..252] Japan) (.:[252..253] .))) ;sentence 4 Span:257..447 ;The c-kit Asp816Val activating mutation is found in all patients with ;mastocytosis with an associated hematologic disorder, and at least in a ;subset of patients with indolent mastocytosis. ;[261..266]:gene-rna:"c-kit" ;[267..270]:variation-state-original:"Asp" ;[270..273]:variation-location:"816" ;[273..276]:variation-state-altered:"Val" ;[288..296]:variation-event:"mutation" ;[328..340]:malignancy:"mastocytosis" ;[425..446]:malignancy:"indolent mastocytosis" (SENT (S (NP-SBJ-1 (DT:[257..260] The) (NML (NN:[261..266] c-kit) (NN:[267..270] Asp) (CD:[270..273] 816) (NN:[273..276] Val)) (VBG:[277..287] activating) (NN:[288..296] mutation)) (VP (VBZ:[297..299] is) (VP (VBN:[300..305] found) (NP-1 (-NONE-:[305..305] *)) (PP-LOC (PP (IN:[306..308] in) (NP (NP (DT:[309..312] all) (NNS:[313..321] patients)) (PP (IN:[322..326] with) (NP (NN:[328..340] mastocytosis))) (PP (IN:[341..345] with) (NP (DT:[346..348] an) (VBN:[349..359] associated) (JJ:[360..371] hematologic) (NN:[372..380] disorder))))) (,:[380..381] ,) (CC:[382..385] and) (PP (ADVP (IN:[386..388] at) (JJS:[389..394] least)) (IN:[395..397] in) (NP (NP (DT:[398..399] a) (NN:[400..406] subset)) (PP (IN:[408..410] of) (NP (NP (NNS:[411..419] patients)) (PP (IN:[420..424] with) (NP (JJ:[425..433] indolent) (NN:[434..446] mastocytosis)))))))))) (.:[446..447] .))) ;sentence 5 Span:448..692 ;The case of an 11-month-old child is presented who was categorized as having ;indolent mastocytosis, and where the Asp816Val mutation was identified in ;lesional skin, but not in bone marrow or in peripheral blood mononuclear ;cell populations. ;[526..547]:malignancy:"indolent mastocytosis" ;[564..567]:variation-state-original:"Asp" ;[567..570]:variation-location:"816" ;[570..573]:variation-state-altered:"Val" ;[574..582]:variation-event:"mutation" (SENT (S (NP-SBJ-6 (NP (DT:[448..451] The) (NN:[452..456] case)) (PP (IN:[457..459] of) (NP (NP (DT:[460..462] an) (ADJP (NML (CD:[463..465] 11) (HYPH:[465..466] -) (NN:[466..471] month)) (HYPH:[471..472] -) (JJ:[472..475] old)) (NN:[476..481] child)) (SBAR-1 (-NONE-:[481..481] *ICH*))))) (VP (VBZ:[482..484] is) (VP (VBN:[486..495] presented) (NP-6 (-NONE-:[495..495] *)) (SBAR-1 (SBAR (WHNP-2 (WP:[496..499] who)) (S (NP-SBJ-2 (-NONE-:[499..499] *T*)) (VP (VBD:[500..503] was) (VP (VBN:[504..515] categorized) (NP-2 (-NONE-:[515..515] *)) (PP (IN:[516..518] as) (S-NOM (NP-SBJ (-NONE-:[518..518] *)) (VP (VBG:[519..525] having) (NP (JJ:[526..534] indolent) (NN:[535..547] mastocytosis))))))))) (,:[547..548] ,) (CC:[549..552] and) (SBAR (WHADVP-5 (WRB:[553..558] where)) (S (NP-SBJ (DT:[559..562] the) (NN:[564..567] Asp) (CD:[567..570] 816) (NN:[570..573] Val) (NN:[574..582] mutation)) (VP (VBD:[583..586] was) (VP (VP (VBN:[587..597] identified) (PP-LOC=3 (IN:[598..600] in) (NP (JJ:[601..609] lesional) (NN:[610..614] skin))) (ADVP-5 (-NONE-:[614..614] *T*))) (,:[614..615] ,) (CC:[616..619] but) (VP (RB:[620..623] not) (PP-LOC=3 (PP (IN:[624..626] in) (NP (NN:[627..631] bone) (NN:[632..638] marrow) (NML-4 (-NONE-:[638..638] *RNR*)))) (CC:[639..641] or) (PP (IN:[642..644] in) (NP (NML (JJ:[646..656] peripheral) (NN:[657..662] blood)) (NML-4 (-NONE-:[662..662] *RNR*)))) (NML-4 (JJ:[663..674] mononuclear) (NN:[675..679] cell) (NNS:[680..691] populations))))))))))) (.:[691..692] .))) ;sentence 6 Span:693..742 ;The significance of these findings is discussed. (SENT (S (NP-SBJ-1 (NP (DT:[693..696] The) (NN:[697..709] significance)) (PP (IN:[710..712] of) (NP (DT:[713..718] these) (NNS:[720..728] findings)))) (VP (VBZ:[729..731] is) (VP (VBN:[732..741] discussed) (NP-1 (-NONE-:[741..741] *)))) (.:[741..742] .))) ;section 7 Span:746..790 ;PMID: 9130517 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[746..750] PMID) (::[750..751] :) (CD:[752..759] 9130517) (IN:[760..761] -LSB-) (NNP:[761..767] PubMed) (HYPH:[768..769] -) (JJ:[770..777] indexed) (IN:[778..781] for) (NNP:[782..790] MEDLINE-RSB-)))